Patients & Caregivers
ARQ 087 Phase 1/2 Clinical Data in iCCA Presented at ASCO 2017
At ASCO 2017, ArQule, Inc. announced that data from a trial with ARQ 087 exhibits significant clinical benefit to iiCCA patients housing FGFR2 fusions.
ASCO: Young AML Patients' Quality of Life Improved by Novartis Therapy CTL019
New data concludes that pediatric and young adult patients saw clinically meaningful quality of life improvements at 3 and 6 months after CTL019 therapy.
ASCO: Does Chemotherapy in Breast and Ovarian Cancer Patients Cause AML and MDS?
New data concludes that the incidence of MDS and AML in ovarian and breast cancer patients was higher in patients exposed to DNA damaging agents.
ASCO: The Cancer Talk — Cost of Care
Dr Warsame noted 4 themes when it came to the 'cost of care' conversations: 1) drug costs, 2) disability, 3) medical bills, and 4) insurance coverage.
ASCO: AML, Glucose Levels, and Treatment Outcomes
Acute myeloid leukemia (AML) generally occurs in older patients, and the older the patient, the more likely he or she will have comorbidities, such as diabetes, that can impact treatment.
Cancer Survivors Consistently Fear Remission
Of the 318 survivors surveyed, 167 (53%) reported fear of cancer recurrence.
Yoga and Exercise Benefit Patients with MPNs
Two studies observed that aerobic activity, massage, yoga, and strength training significantly reduced disease burden using the MPN-SAF TSS scale.
ASCO: Most Polycythemia Vera Patients Are Not Taking Cytoreductive Medications
Patients with uncontrolled PV have an increased risk of cardiovascular complications such as stroke, pulmonary embolism, deep vein thrombosis and heart attack.
ASCO Preview: Game Changing Breakthrough for Merkel Cell Carcinoma?
Of the 4 patients give triple therapy, 3 obtained complete remission of the rare skin cancer.
FDA Approves Zykadia (ceritinib) As First Line Therapy for Rare Lung Cancer
Median PFS was 16.6 months in the Zykadia treated group compared to 8.3 months for the group given standard chemotherapy
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.